Bristol Myers Squibb Witnesses Strong Demand For ‘Newer Drugs’ As Q2 Earnings Beat Expectations, Raises 2024 Profit Forecast
Bristol Myers Squibb Witnesses Strong Demand For ‘Newer Drugs’ As Q2 Earnings Beat Expectations, Raises 2024 Profit Forecast Friday, Bristol Myers Squibb & Co (NYSE:BMY) posted second-quarter revenues of $12.20 billion, beating the consensus of $11.55 billion, an increase of 9% year-over-year, or 11% when adjusted for foreign exchange impacts, primarily driven by the Growth Portfolio and Eliquis. […]